ArticleVirus research2026
Discovery and structural characterization of newcastle disease virus mimetic peptides identified through phage display.
Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in precision medicine and virotherapy have expanded the search for novel biomolecules with therapeutic potential. In this study, we employed a phage display-based platform to identify and characterize mimetic peptides of the Newcastle Disease Virus (NDV), a promising agent in oncolytic virotherapy and veterinary vaccinology. Following the immunization of gallus domesticus (White Leghorn) and the high-performance liquid chromatography (HPLC) purification of specific IgY antibodies, a Ph.D.-7™ phage library was screened against anti-NDV targets. We identified three high-affinity mimotopes (NDV-1, NDV-2, and NDV-3) that were further characterized through an integrated in silico workflow involving AlphaFold2 and PEP-FOLD3. Structural analysis revealed that NDV-3 exhibits a stable helical conformation, which correlates with its superior binding affinity observed in Phage-ELISA assays. Furthermore, B-cell epitope predictions (BepPred-3.0) highlighted the immunogenic potential of NDV-1. Our findings demonstrate a robust proof-of-concept for the identification of NDV-mimetic leads, providing a structural basis for the future development of targeted oncolytic strategies and next-generation avian vaccines. Further functional assays are required to validate the translational efficacy of these candidates in clinical and veterinary settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.